DE4229879A1 - Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood - Google Patents

Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood

Info

Publication number
DE4229879A1
DE4229879A1 DE4229879A DE4229879A DE4229879A1 DE 4229879 A1 DE4229879 A1 DE 4229879A1 DE 4229879 A DE4229879 A DE 4229879A DE 4229879 A DE4229879 A DE 4229879A DE 4229879 A1 DE4229879 A1 DE 4229879A1
Authority
DE
Germany
Prior art keywords
oxytocin
thyroid
blood
none
hypo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4229879A
Other languages
German (de)
Inventor
Des Erfinders Auf Nennung Verzicht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE
Original Assignee
KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE filed Critical KNAUF SIEGFRIED 06567 BAD FRANKENHAUSEN DE
Priority to DE4229879A priority Critical patent/DE4229879A1/en
Publication of DE4229879A1 publication Critical patent/DE4229879A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides

Abstract

"Oxytocin" is used as a medicament for thyroid hypo- or hyperfunction in humans having none or insufficient Oxytocin in the blood. The thyroid gland has hormone receptors for binding the neural hormone oxytocin. The activation of tyrosine in the thyroid gland is dependent on the level of oxytocin in the blood. A lack of oxytocin results in a lack of tyrosine in the thyroid gland, and no thyroid hormone is formed in the thyroid gland.

Description

Ca. 15 mill. Menschen leiden in unserem Land an Schilddrüsen­ problemen. Bisher galt die Meinung, daß das Problem darin liegt das die Patienten die daran leiden zu wenig Jod aufnehmen. Ich bin der Meinung und meine bisherige Forschung in diesem Ge­ biet zeigt mir, daß das Problem nicht allein im Jodmangel liegt. Das Problem liegt bei vielen Menschen im Fehlen des Neurohormons Oxytocin. Es besteht aus 9 Aminosäuren. Die wichtigste Aminosäu­ re in der Schilddrüse ist das Tyrosin, aus dem sich dann die ei­ gentlichen Schilddrüsenhormone Thyroxin und Trÿodthyronin auf­ bauen. Das Tyrosin in der Schilddrüse hat die Aufgabe das anorga­ nische Jod im Blut aufzunehmen, dabei entsteht das Dÿodtyrosin und aus dem Dÿodtyrosin werden die Schilddrüsenhormone Thyroxin sowie Trÿodthyronin gebildet.Approx. 15 mill. People suffer from thyroid glands in our country problems. So far, the opinion has been that the problem lies in it that the patients suffering from it take in too little iodine. I think and my previous research in this ge bid shows me that the problem is not just iodine deficiency. The problem with many people is the lack of the neurohormone Oxytocin. It consists of 9 amino acids. The most important amino acid Right in the thyroid gland is the tyrosine, from which the egg then emerges the thyroid hormones thyroxine and triodothyronine to build. The tyrosine in the thyroid gland has the task of anorga to take up niche iodine in the blood, which produces dododyrosine and the dododyrosine becomes the thyroid hormone thyroxine and Trÿodthyronin formed.

Ich bin der Meinung, das die Schilddrüse Hormonrezeptoren be­ sitzt, wo sich das Neurohormon Oxytocin binden kann. Das bedeutet das die Aktivierung des Tyrosins in der Schilddrüse abhängig ist vom Oxytocin im Blut. Durch eine negative Information im Unterbewußtsein wird kein Oxytocin mehr vom Hypophysenhinter­ lappen ins Blut abgegeben. Das führt dazu das kein Tyrosin mehr in der Schilddrüse gebildet wird und somit auch keine Schilddrüsen­ hormone mehr in der Schilddrüse aufgebaut werden. Hormonrezepto­ ren wo Oxytocin wirkt wurden bisher nur an der Gebärmutter und an den Milchdrüsen nachgewiesen.I think the thyroid gland has hormone receptors sits where the neurohormone oxytocin can bind. That means which depends on the activation of tyrosine in the thyroid is from oxytocin in the blood. By negative information in the Oxytocin no longer becomes subconscious from the pituitary behind rags into the blood. This means that no more tyrosine is formed in the thyroid gland and therefore no thyroid glands hormones are more built up in the thyroid. Hormone receptor Where oxytocin acts have so far only been found on the uterus and detected on the mammary glands.

Literaturnachweis
Schenck/Kolb Grundriß der Physiologischen Chemie Veb Gustav Fischer Verlag Jena 4. Auflage 1961 Seite 141-142 Markward Allgemeine und spezielle Pharmakologie VEB Verlag Volk und Gesundheit Berlin 1972 Seite 177-180.
Bibliography
Schenck / Kolb Outline of Physiological Chemistry Veb Gustav Fischer Verlag Jena 4th edition 1961 page 141-142 Markward General and special pharmacology VEB Verlag Volk und Gesundheit Berlin 1972 page 177-180.

Der in Patentanspruch 1 angegebenen Erfindung liegt das Problem zugrunde, das durch die Gabe von Schilddrüsenhormonen, wie sie zur Zeit in der Behandlung angeboten werden, sich bei solchen Menschen die kein Oxytocin im Blut haben, keine Besserung einstellt. The invention specified in claim 1 is the problem based on the administration of thyroid hormones, such as those used for Time in treatment can be offered to such people who have no oxytocin in the blood, does not improve.  

Teilweise verschlechtert sich der Gesundheitszustand und es muß operiert werden, es kommt auch teilweise zu Nebenwirkungen. Ich habe bereits versucht mit 2 Instituten in Göttingen und einem Pharmahersteller Kontakt aufgenommen, hatte aber keinen Erfolg. Der Grund hierfür ist, den Beweis zu erbringen, das die Schild­ drüse Hormonrezeptoren besitzt, wo sich das Neurohormon Oxytocin binden kann. Ich werde weiterhin versuchen diesen Beweis zu er­ bringen, eventuell könnten Sie mir dabei helfen.Sometimes the state of health deteriorates and it has to operated, there are also some side effects. I have already tried with 2 institutes in Göttingen and one Pharmaceutical manufacturers contacted, but had no success. The reason for this is to provide evidence that the shield gland has hormone receptors, where the neurohormone oxytocin can bind. I will continue to try this proof maybe you could help me with that.

Es bleibt mir nichts anderes übrig, als vorher das Patent anzu­ melden. Denn ich muß damit rechnen, das wenn ich von einem In­ stitut so ein Experiment durchführen lassen möchte, daß das Institut später absagt, selber in dieser Richtung forscht und dieses als Patent für sich anmeldet.I have no choice but to apply for the patent beforehand Report. Because I have to reckon with the fact that if I come from an In would like to have such an experiment carried out that the Institute later canceled, itself researches in this direction and registers this as a patent.

Das Problem der Schilddrüsen Unter- bzw. Überfunktion kann durch Gabe von Oxytocin wieder normalisiert werden.The problem of underactive or overactive thyroid can be caused by Administration of oxytocin can be normalized again.

Die mit der Erfindung erreichten Vorteile bestehen darin, das hier ein Medikament gegeben wird, das genau im Aufbau dem ei­ gentlichen Neurohormon was aus dem Hypophysesenhinterlappen nicht mehr ausgeschieden wird, entspricht. Es treten somit keine Nebenwirkungen auf und eine Operation an der Schilddrüse muß nicht durchgeführt werden. Es tritt somit wieder eine Normali­ sierung der Schilddrüsentätigkeit ein. Außerdem werden gro­ ße Kosten wie sie bisher zur Behandlung bei Schilddrüsenproble­ men nötig waren eingespart.The advantages achieved with the invention are that Here a drug is given that is exactly the same as the egg genetic neurohormone what comes from the pituitary gland is no longer eliminated. So there are none Side effects on and thyroid surgery must be done not be carried out. A normali occurs again increase in thyroid activity. They also become big esse costs as previously for the treatment of thyroid problems men were saved.

Zusammensetzung des Neurohormons OxytocinComposition of the neurohormone oxytocin

Claims (1)

"Oxitocin" als neues Medikament zur Bekämpfung von Schild­ drüsen-Unterfunktion und -Überfunktion, dadurch gekennzeichnet, daß dieses Medikament nur Anwendung findet bei Menschen die zu wenig oder kein Oxitocin im Blut haben."Oxitocin" as a new drug to combat hypothyroidism and hyperfunction, characterized in that this drug is only used in people who have too little or no oxitocin in the blood.
DE4229879A 1992-09-04 1992-09-04 Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood Withdrawn DE4229879A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4229879A DE4229879A1 (en) 1992-09-04 1992-09-04 Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4229879A DE4229879A1 (en) 1992-09-04 1992-09-04 Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood

Publications (1)

Publication Number Publication Date
DE4229879A1 true DE4229879A1 (en) 1994-03-10

Family

ID=6467414

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4229879A Withdrawn DE4229879A1 (en) 1992-09-04 1992-09-04 Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood

Country Status (1)

Country Link
DE (1) DE4229879A1 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORTH, W. et. al: Pharmakologie und Toxikologie, BI-Wiss. Verlag, Mannheim 1988, 5. Aufl., S. 407-409 *
LANG, F.: Patophysiologie, Pollenbiochemie, Enke, Stuttgart 1983, S. 362-364 *

Similar Documents

Publication Publication Date Title
Wilber et al. The effect of glucocorticoids on thyrotropin secretion
Taber et al. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors
Baselt et al. Disposition of toxic drugs and chemicals in man
DE59207523C5 (en) Prepn. of compsn. contg. human protein and pharmaceuticals for infusion - contains preservatives which are opt. removed before storage, for germ free prod. giving minimal pain upon application
Collins Kindling of neuroanatomic pathways during recurrent focal penicillin seizures
EP1037648B1 (en) The use of erythropoietin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases
Greenough III et al. Hypoglycaemia and hyperinsulinaemia in response to raised free-fatty-acid levels
DE4040911A1 (en) TWO-PIECE DEVICE FOR THE CONTROLLED ADMINISTRATION OF ACTIVE SUBSTANCE
DE69105202T2 (en) SYSTEM FOR THE ADMINISTRATION OF MEDICINES BY A TWO-STAGE IONTOPHORESIS PROCESS.
DE19740733A1 (en) Powder composition containing absorbent resin and peptide
EP0378137A3 (en) Galenical form
GOLDFINE et al. Stimulation of the uptake of α-aminoisobutyric acid in rat thymocytes by L-triiodothyronine: A comparison with insulin and dibutyryl cyclic AMP
DE3510654A1 (en) NEW PHARMACEUTICAL APPLICATION OF CGRPS
Wertheim et al. ADRENOCORTICAL INFLUENCES ON FREE‐OPERANT AVOIDANCE BEHAVIOR 1
DE4229879A1 (en) Oxytocin as medicament for thyroid hypo= and hyper-function - in humans having none or insufficient oxytocin in the blood
EP0273407B1 (en) Medicine for improving the specific properties of blood
DE10228680A1 (en) Basis for transdermal formulations (PTF)
Bethge Die steroidinduzierte Nebennierenrindenunterfunktion: Pathogenese, Klinik, Diagnostik, Prophylaxe und Therapie
US5468726A (en) Treatment of neuropsychiatric disorders
DE69533742T2 (en) Use of proline and / or derivatives as anti-hepatitis agents
WO2001080871A2 (en) Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
DE2657382A1 (en) ORAL ANTIDIABETIC
EP0098975A1 (en) Biostimulating drug
AT367292B (en) DEVICE IMPLANTABLE INTO THE BODY FOR CONSTANT DELIVERY OF AN ACTIVE SUBSTANCE
Uthne Preliminary studies of somatomedin in vitro and in vivo in rats

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8122 Nonbinding interest in granting licences declared
8139 Disposal/non-payment of the annual fee